Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of eight psychiatric medications: - **Quetiapine and Olanzapine**: Atypical antipsychotics that work by antagonizing multiple neurotransmitter receptors, including serotonin 5-HT2A and dopamine D2 receptors. - **Mirtazapine**: An atypical antidepressant that enhances noradrenergic and serotonergic neurotransmission through antagonism of central α2-adrenergic autoreceptors. - **Carbamazepine**: An anticonvulsant and mood stabilizer that works by blocking sodium channels. - **Sertraline**: A selective serotonin reuptake inhibitor (SSRI) antidepressant. - **Amitriptyline**: A tricyclic antidepressant that inhibits the reuptake of serotonin and norepinephrine. - **Chlorpromazine**: A first-generation (typical) antipsychotic that blocks dopamine D2 receptors. - **Risperidone**: An atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. This specific combination is not a standard treatment regimen and would represent polypharmacy with significant risk of drug interactions and additive side effects, including anticholinergic effects, sedation, metabolic effects, and cardiac risks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quetiapine + olanzapine + mirtazapine + carbamazepine + sertraline + amitriptyline + chlorpromazine + risperidone.